Dear editor,rnA scheme for treating COVID-19 was published in NSR in April[1]based on blocking the translation of very large vi-ral proteins.Since then,additional sup-porting data have greatly strengthened the proposal.The drug,HHT(homo-harringtonine,or omacetaxine),is read-ily available and inexpensive as it has been approved since 2012 for treating leukemia.The in vitro and in vivo data clearly justify the planning of clinical tri-als.Given the specific mechanism,we be-lieve a trial of modest scale would be sufficient to prove,or disprove,the effi-cacy of the treatment scheme.Such trials,however,are only feasible in regions with many new infections.